(Q37638674)

21 August 2017

1 reference

title

Pantoprazole: a proton pump inhibitor (English)

1 reference

21 August 2017

Luis Moreira Dias

1

1 reference

21 August 2017

publication date

1 January 2009

1 reference

Clinical Drug Investigation

21 August 2017

published in

1 reference

21 August 2017

volume

29 Suppl 2

1 reference

21 August 2017

page(s)

3-12

1 reference

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]

21 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F1153121-S0-000000000-00000

The use of proton pump inhibitors in children: a comprehensive review

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F1153121-S0-000000000-00000

Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study

21 January 2018

1 reference

12 December 2020

The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England

1 reference

12 December 2020

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease

1 reference

12 December 2020

Medical treatments in the short term management of reflux oesophagitis

1 reference

12 December 2020

Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents

1 reference

12 December 2020

One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis

1 reference

12 December 2020

Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse

1 reference

12 December 2020

The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients

1 reference

12 December 2020

The role of proton pump inhibitors in gastro-oesophageal reflux disease

1 reference

12 December 2020

Guide to the use of proton pump inhibitors in adult patients

1 reference

12 December 2020

Pharmacokinetics of proton pump inhibitors in children

1 reference

12 December 2020

Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors

1 reference

12 December 2020

Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates

1 reference

12 December 2020

Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study

1 reference

12 December 2020

Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults

1 reference

12 December 2020

Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole

1 reference

12 December 2020

Prevention of erosive oesophagitis relapse with pantoprazole

1 reference

12 December 2020

Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD).

1 reference

12 December 2020

Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.

1 reference

12 December 2020

Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children

1 reference

12 December 2020

Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease

1 reference

12 December 2020

Pantoprazole versus lansoprazole in French patients with reflux esophagitis.

1 reference

12 December 2020

A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease.

1 reference

12 December 2020

Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients

1 reference

12 December 2020

Classifications of esophagitis: who needs them?

1 reference

12 December 2020

Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population

1 reference

12 December 2020

Pharmacokinetic drug interaction profiles of proton pump inhibitors

1 reference

12 December 2020

Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

1 reference

12 December 2020

Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors

1 reference

12 December 2020

Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis

1 reference

12 December 2020

Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders

1 reference

12 December 2020

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man

1 reference

12 December 2020

A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease

1 reference

12 December 2020

40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms

1 reference

12 December 2020

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

1 reference

12 December 2020

Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study

1 reference

12 December 2020

Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease

1 reference

12 December 2020

The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus

1 reference

12 December 2020

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

1 reference

12 December 2020

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

1 reference

12 December 2020

Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study

1 reference

12 December 2020

Restoration of acid secretion following treatment with proton pump inhibitors

1 reference

12 December 2020

Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

1 reference

12 December 2020

Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know

1 reference

12 December 2020

Prevention of chronic NSAID induced upper gastrointestinal toxicity

1 reference

12 December 2020

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up

1 reference

12 December 2020

Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients.

1 reference

12 December 2020

Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

1 reference

12 December 2020

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers

1 reference

12 December 2020

10.2165/1153121-S0-000000000-00000

Identifiers

DOI

1 reference

21 August 2017

1 reference